Alnylam Pharmaceuticals
Why Robinhood?
Robinhood gives you the tools you need to put your money in motion. You can buy or sell ALNY and other ETFs, options, and stocks.About ALNY
Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company. It engages in the business of developing and commercializing novel therapeutics based on ribonucleic acid interference.
ALNY Key Statistics
Stock Snapshot
As of today, Alnylam Pharmaceuticals(ALNY) shares are valued at $453.97. The company's market cap stands at 60.08B, with a P/E ratio of 1888.39.
As of 2025-11-14, Alnylam Pharmaceuticals(ALNY) stock has fluctuated between $447.16 and $456.14. The current price stands at $453.97, placing the stock +1.5% above today's low and -0.5% off the high.
The Alnylam Pharmaceuticals(ALNY)'s current trading volume is 666.07K, compared to an average daily volume of 1.05M.
In the last year, Alnylam Pharmaceuticals(ALNY) shares hit a 52-week high of $495.55 and a 52-week low of $205.87.
In the last year, Alnylam Pharmaceuticals(ALNY) shares hit a 52-week high of $495.55 and a 52-week low of $205.87.
ALNY News
Wells Fargo analyst Tiago Fauth raised the firm’s price target on Alnylam (ALNY) to $479 from $395 and keeps an Equal Weight rating on the shares. The firm beli...
No investment is a slam dunk to double your money. But these great stocks appear to have what it takes. Some stocks are similar to the tortoise in Aesop's famo...
Below is Validea's guru fundamental report for ALNYLAM PHARMACEUTICALS, INC. (ALNY). Of the 22 guru strategies we follow, ALNY rates highest using our Twin Mome...
Analyst ratings
69%
of 32 ratingsMore ALNY News
Alnylam (ALNY) Pharmaceuticals announced results from new post hoc analyses of the HELIOS-B Phase 3 study of AMVUTTRA, an RNAi therapeutic approved for the trea...
Alnylam Pharmaceuticals (ALNY) shared new results from its Phase 3 HELIOS-B study of vutrisiran, with data presented at the American Heart Association meeting....
Alnylam Pharmaceuticals recently reported that third-quarter revenue rose to US$1.25 billion from US$500.92 million a year earlier, swinging from a net loss to...